Equities Analysts Set Expectations for ARTL FY2025 Earnings

Artelo Biosciences, Inc. (NASDAQ:ARTL) – HC Wainwright cut their FY2025 earnings per share estimates for Artelo Biosciences in a report issued on Tuesday, March 4th. HC Wainwright analyst V. Bernardino now expects that the company will post earnings of ($1.84) per share for the year, down from their prior forecast of ($1.61). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Artelo Biosciences’ current full-year earnings is ($2.62) per share.

Artelo Biosciences (NASDAQ:ARTL) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.43).

Several other equities research analysts also recently issued reports on ARTL. LADENBURG THALM/SH SH upgraded shares of Artelo Biosciences to a “strong-buy” rating in a research note on Wednesday, December 25th. D. Boral Capital reiterated a “buy” rating and set a $6.00 target price on shares of Artelo Biosciences in a research note on Thursday, February 27th.

Artelo Biosciences Price Performance

Shares of ARTL stock opened at $1.02 on Thursday. The company has a fifty day moving average price of $1.17 and a two-hundred day moving average price of $1.15. Artelo Biosciences has a one year low of $0.91 and a one year high of $1.70. The stock has a market cap of $3.29 million, a P/E ratio of -0.36 and a beta of 1.06.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.